In vivo antitumor activity of S 16020-2, a new olivacine derivative

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 6, 1996, Pages 513-521

  Guilbaud, N ^a   Kraus Berthier, L ^a   Saint Dizier, D ^a   Rouillon, M H ^a   Jan, M ^a   Burbridge, M ^a   Visalli, M ^a   Bisagni, E ^b   Pierre A ^a   Atassi, G ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b Section de Biologie   (France)

Author keywords

Multidrug resistance; S 16020 2; Topoisomerase II; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ELLIPTINIUM ACETATE; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA B16; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BONE MARROW; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ELLIPTICINES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LEUKEMIA P388; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 9544232543     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050520     Document Type: Article

References (18)

1. Auclair C, Pierre A, Voisin E, Pepin O, Cros S, Colas C, Saucier JM, Verschuere B, Gros P, Paoletti C (1987) Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl) 9-hydroxy ellipticinium-chloride, HCl. Cancer Res 47:6254
2. Banks-Schlegel SP, Gadzar AF, Harris CC (1985) Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Caner Res 45:1187
3. Boven E, Winograd B, Fodstad O, Lobbezoo MW, Pinedo HM (1988) Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol 24:567
4. De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F (1990) Evidence of DNA-topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukaemia cells. Mol Pharmacol 37:11
5. Fosse P, Rene B, Charra M, Paoletti C, Saucier JM (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol 42:590
6. Geran RI, Greenberg NH, McDonald MM, Schumacher AM, Abott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:9
7. Gianni L, Corden BJ, Meyers E (1983) The biochemical basis of anthracycline toxicity and antitumor activity. In: Hodgson E, Bend JR, Philpot RM (eds) Reviews in biomedical toxicology. Elsevier, New York, p 1
8. Jaztold-Howorko R, Landras C, Pierre A, Atassi G, Guilbaud N, Kraus-Berthier L, Leonce S, Rolland Y, Prost JF, Bisagni E (1994) Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido [4,3-b] carbazole-1-[N-(dialkylamino) alkyl] carboxamides, a new promising series of antitumor olivacine derivatives. J Med Chem 37:2445
9. Khayat D, Rixe O (1994) Protocoles et traitements des effets secondaires. In: Arnette SA (ed) Chimiotherapie anticancereuse. p 58
10. Kraus-Berthier L, Guilbaud N, Saint-Dizier D, Pierre A, Léonce S, Bisagni E, Rolland Y, Atassi G (1994) Preclinical antitumor activity of a new olivacine derivative S 16020-2. (abstr 046) Proceedings. 8th NCl-EORTC symposium on new drugs in cancer therapy. Ann Oncol 5 [Suppl 5] : 80
11. Le Mee S, Markovits J, Pierre A, Atassi G, Bisagni E, Jaquemin-Sablon A, Saucier JM (1994) In vitro studies of S 16020-2, a new antitumor pyridocarbazole derivative. Proceedings, 5th conference on DNA topoisomerases in therapy, New York, (Oct., 3-6)
12. Perez V, Pierré A, Leonce S, Anstett M, Prost JF, Atassi G (1993) Caractérisation in vitro de l'activité du S 9788, un nouveau modulateur de la résistance multidrogue. Bull Cancer 80:310
13. Rouesse J, Spielmann M, Turpin F, Le Chevalier T, Azab M, Mondesir JM (1993) Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer 29A:856
14. Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion from a breast carcinoma. J Natl Cancer Inst 51:1409
15. Till JE, McCulloch EA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213
16. Yang JM, Goldenberg S, Gottesman M, Hait W (1994) Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 54:730
17. Zuckermann KS, Lobuglio AF, Reeves JA (1990) Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen. J Clin Oncol 8:248
18. Zunino F, Capranico G (1990) DNA topoisomerase II as the primary target of antitumor anthracyclines. Anticancer Drug Des 5:307